Form 8-K Pacira Pharmaceuticals, For: Nov 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacira Pharmaceuticals (PCRX) PT Raised to $55 at Piper Jaffray
November 1, 2018 1:13 PM EDTPiper Jaffray analyst David Amsellem raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $55.00 (from $51.00) while maintaining a Overweight rating.
Amsellem cited a clear uptick in Exparel sales growth.
... More